News

Filter

Current filters:

AranespRegulation

US FDA modifies dosing for ESA’s Aranesp, Epogen and Procrit on cardiovascular risks

27-06-2011

The US Food and Drug Administration on Friday recommended more conservative dosing guidelines for erythropoiesis-stimulating…

AmgenAranespBiotechnologyEpogenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalProcritRegulation

New guideline from ASH and ASCO recommends caution regarding ESA use in cancer patients

28-10-2010

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical…

AmgenAranespBiotechnologyEpogenImmunologicalsJohnson & JohnsonOncologyPharmaceuticalProcritRegulation

Further re-evaluation of ESA anemia drugs proposed by US FDA officials

07-01-2010

In An article published in the prestigious New England Journal of Medicine yesterday, a US Food and Drug…

AmgenAranespBiotechnologyDarbepoetin AlfaEpoetin AlfaEpogenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalProcritRegulation

Amgen’s Aranesp did not meet endpoints and increased risk of stroke; firm accused of kickbacks

02-11-2009

Leading US biotechnology firm Amgen suffered a double dose of bad news on October 30, when the firm revealed…

AmgenAranespBiotechnologyDarbepoetin AlfaGeneralNorth AmericaOncologyRegulation

Back to top